Drug Profile
Etazolate
Alternative Names: EHT 202; EHT-0202Latest Information Update: 30 Aug 2019
Price :
$50
*
At a glance
- Originator ExonHit Therapeutics
- Developer Eurobio Scientific; ExonHit Therapeutics
- Class Antiarrhythmics; Antipsychotics; Nicotinic acids; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Amyloid precursor protein secretase inhibitors; GABA A receptor modulators; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Parkinson's disease; Retinal disorders; Vascular dementia
Most Recent Events
- 19 Dec 2012 ExonHit Therapeutics has merged with InGen Biosciences to form Diaxonhit
- 15 Mar 2011 Etazolate is available for licensing as of 15 Mar 2011. http://www.exonhit.com/
- 30 Oct 2009 Efficacy & adverse events data from a phase IIa trial in Alzheimer's disease presented at the 2nd Conference of Clinical Trials on Alzheimer's Disease (CTAD-2009)